Categories
Anticancer Drugs Oncology Pharmacology Physiotherapy

FOLFOX

In this article, we will discuss FOLFOX. So, let’s get started. FOLFOX is a combination of chemotherapy (chemo) drugs used in the treatment of cancer of the bowel. It is sometimes known as FLOX. FOLFOX chemo is given through an intravenous line (IV). The type of IV is called a PICC line. PICC stands for […]

Categories
Anticancer Drugs Oncology Pharmacology Physiotherapy Rucaparib

Rucaparib (Description)

In this article, we will discuss Rucaparib (Description). So, let’s get started. Rucaparib is a targeted cancer therapy belonging to the class of drugs known as PARP inhibitors. Here’s a brief description: Mechanism of Action: Rucaparib works by inhibiting the activity of poly (ADP-ribose) polymerase (PARP), an enzyme involved in DNA repair. By blocking PARP, […]

Categories
Anticancer Drugs Oncology Pharmacology Physiotherapy Rucaparib

Rucaparib (Uses)

In this article, we will discuss Rucaparib (Uses). So, let’s get started. Rucaparib is a medication used in the treatment of certain types of cancer. Specifically, it is a poly ADP-ribose polymerase (PARP) inhibitor. Here are the main uses of Rucaparib: Ovarian Cancer: Rucaparib is approved for the maintenance treatment of recurrent ovarian cancer. It […]

Categories
Anticancer Drugs Oncology Pharmacology Physiotherapy Sulindac

Sulindac and Cardiac Damage

Sulindac Protects Cardiac Myocytes Against Oxidative Damage The initial experiments were designed to determine whether sulindac could protect primary neonatal cardiac myocytes in culture against oxidative damage. The cardiac myocytes were exposed to hypoxia and reoxygenation to promote oxidative damage in the presence or absence of sulindac. Cell viability was then assayed by LDH release. […]

Categories
Anticancer Drugs Olaparib Oncology Pharmacology Physiotherapy

Olaparib: News

The PARP inhibitor olaparib has already shown promise in treating patients with ovarian and breast cancers who have BRCA1 or BRCA2 germline mutations. Now, a study reported in the Journal of Clinical Oncology has found that the drug also shrinks prostate and pancreatic tumors in people who have these mutations. BRCA mutations disable DNA damage […]